دورية أكاديمية
Reply to 'Letter to the editor on 'Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC'.
| العنوان: | Reply to 'Letter to the editor on 'Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC'. |
|---|---|
| المؤلفون: | Ou, Sai-Hong I., Janne, Pasi |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2014 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Letter to the editor |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://annonc.oxfordjournals.org/cgi/content/short/mdu258v1Test; http://dx.doi.org/10.1093/annonc/mdu258Test |
| DOI: | 10.1093/annonc/mdu258 |
| الإتاحة: | https://doi.org/10.1093/annonc/mdu258Test http://annonc.oxfordjournals.org/cgi/content/short/mdu258v1Test |
| حقوق: | Copyright (C) 2014, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.F3BB47F7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdu258 |
|---|